NCT05406063招募中不适用
Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases a Multicentre Prospective, Open Label, Randomised Controlled Phase 3 Non-inferiority Clinical Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 162
- 试验地点
- 4
- 主要终点
- Pain relief (response rate) measured with the Visual Analog Scale (VAS) from Baseline to 3 months after treatment.
研究概览
简要总结
To investigate, whether multi-fraction stereotactic body radiation therapy (SBRT) within 3 treatment fractions is non-inferior to the current standard of care of 5 fraction SBRT regarding pain response at 3 months after radiotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Personally signed and dated written informed consent,
- •Histological diagnosis of malignancy,
- •Histologically or radiologically diagnosed bone metastasis,
- •Age ≥ 18 years
- •Pain or under pain control medication
排除标准
- •Pregnant or lactating women,
- •Women of childbearing potential or sexually active males not willing to use effective contraception while on treatment and 3 months after the end of treatment,
- •Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.,
- •Prior radiotherapy to the intended treatment site,
- •Lesions > 5cm in maximum diameter,
- •Prior treatment with radioactive isotopes within 30 days of randomisation,
- •Spinal column, hands, feet, or head as intended treatment site,- Fracture at the intended treatment site,
- •Surgery required or previous surgery at the intended treatment site
- •Instability of the intended treatment site.
结局指标
主要结局
Pain relief (response rate) measured with the Visual Analog Scale (VAS) from Baseline to 3 months after treatment.
时间窗: Baseline and 3 months after treatment
The Visual Analog Scale is a validated, subjective measure for pain. Possible scores ranges between zero (no pain) and ten (worst possible pain). The primary endpoint was defined as pain relief \> 2 points from Baseline to 3 months after treatment.
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
招募中
3 期
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerLocally Advanced Lung Non-Small Cell CarcinomaStage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8NCT05624996NRG Oncology474
招募中
3 期
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerNCT05946213NRG Oncology1,209
终止
3 期
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)Non-Small Cell Lung CancerNCT03924869Merck Sharp & Dohme LLC448
终止
不适用
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular CarcinomaHepatocellular CarcinomaLiver CancerNCT01005875University of Alabama at Birmingham5
已完成
不适用
Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain MetastasesBrain CancerNeoplasm MetastasisCancer of Brain and Nervous SystemMetastatic Malignant Neoplasm to BrainNCT00928226Stanford University56